The new model provides a framework for predicting the development of multi-drug resistance in HIV patients.
The emergence of drug resistant forms of HIV often underlies the failure of current antiretroviral therapies for HIV infection. Specific mutations in the HIV genome confer resistance to individual drugs. Recombination, a process similar to sexual reproduction in higher organisms, can accelerate the accumulation of resistance mutations by mixing the contents of distinct viral genomes and expedite the failure of therapy. The dynamics of the emergence of recombinant forms of HIV in infected individuals remains poorly understood.
AIDS/HIV - Clinical Features
Encyclopedia section of medindia gives general info about HIV Clinical Features
Advertisement
In a study publishing in PLoS Computational Biology on October 26, 2007, researchers Suryavanshi and Dixit from the Indian Institute of Science, Bangalore, India present a new model of HIV dynamics that provides a detailed account of the emergence and growth of recombinant forms of HIV following infection with diverse viral genomes. Analysis of experimental data using the model establishes the high rate of HIV recombination and elucidates the origins of scaling relationships that link the relative prevalence of recombinant forms of HIV to the overall extent of infection. The model provides a framework for predicting the development of multi-drug resistance in HIV patients.
Source: Eurekalert
VEN/S
VEN/S
HIV Vaccine Developed by Russia Offers Hope for Patients
Russian scientists have developed a potential HIV vaccine.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest AIDS/HIV News
The 35th World AIDS Day (WAD) marks an opportunity to review strides in HIV prevention, control, and management, acknowledging achievements.
World AIDS Day 2023 focuses on the theme 'Let Communities Lead,' emphasizing the power of the communities most affected by HIV in bringing an end to AIDS.
Young men involved in sexual activity with other guys are less aware and stigmatized to access PrEP, an HIV prevention drug.
Though monkeypox can affect anyone, CDC research states that approximately 40% of people diagnosed with monkeypox in the US also test positive for HIV.
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.